New Teva/APP Gemzar will further test Lilly's generic-threatened revenues
This article was originally published in Scrip
Executive Summary
The next few quarters will provide a key indicator of how robust Lilly's revenues are likely to be in the face of generic alternatives to its key drugs. Following a defeat in a US appeals court in November 2010which in effect invalidated Gemzar's use patent, another generic version of Gemzar has been launched by Teva Pharmaceutical Industries and APP Pharmaceuticals. This version, provided in 200mg and 1 g single dose vials, under an agreement signed by the two companies, follows Teva's FDA approval on 25 January.